Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Dressel, Alexander [VerfasserIn]   i
 Grammer, Tanja B. [VerfasserIn]   i
 März, Winfried [VerfasserIn]   i
Titel:Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease
Titelzusatz:Insights from the Ludwigshafen Risk and Cardiovascular Health cohort
Verf.angabe:Alexander Dressel, Burkhard Schmidt, Nina Schmidt, Ulrich Laufs, Felix Fath, M. John Chapman, Tanja B. Grammer, Winfried März
E-Jahr:2019
Jahr:14 June 2019
Umfang:8 S.
Fussnoten:Gesehen am 06.11.2019
Titel Quelle:Enthalten in: Vascular pharmacology
Ort Quelle:New York, NY : Elsevier, 2002
Jahr Quelle:2019
Band/Heft Quelle:120(2019) Artikel-Nummer 106566, 8 Seiten
ISSN Quelle:1879-3649
Abstract:Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) reduce cardiovascular events in coronary artery disease (CAD). Their costs exceed that of established oral lipid-lowering agents. Previous cost-effectiveness assessments have been inconsistent. Markov cohort state transitions models for stable CAD patients were calculated using information from 1530 participants of the Ludwigshafen Risk and Cardiovascular Health Study (LURIC) with known causes of deaths. Non-fatal to fatal event rates, drug prices, direct treatment costs, and utility weights were from public sources. At an assumed relative risk reduction of 32.5% and an annual drug price of 8500 Euros, QALYs gained were 1.23 and 1.20, savings were 2390 and 2410 Euros, and ICERs were 112,530 and 108,660 Euros in women and men, respectively. When the annual cost of this medication was set at 1600 Euros, corresponding ICERs were 21,180 and 20,450 Euros. PCSK9i treatment is cost-effective in stable CAD at a threshold of 150,000 Euro and annual costs of 8500 Euros. As the broad use of PCSK9i therapy in CAD would have a disruptive impact on the healthcare budget, treatment should be focused on very high risk patients (≥3 comorbidities, annual risk of 10%); alternatively, and for lower risk, significant cost reductions would be needed.
DOI:doi:10.1016/j.vph.2019.106566
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.vph.2019.106566
 Volltext: http://www.sciencedirect.com/science/article/pii/S1537189118304336
 DOI: https://doi.org/10.1016/j.vph.2019.106566
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Cardiovascular risk
 Coronary heart disease
 Cost-effectiveness
 Incremental cost-effectiveness ratio (ICER)
 LDL cholesterol
 Proprotein convertase subtilisin/kexin type 9 PCSK9)
 Quality Adjusted Life Years (QALYs)
K10plus-PPN:1681170868
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68451030   QR-Code
zum Seitenanfang